Metformin Shows Promise in Lung Cancer Treatment

New research suggests that metformin, a common diabetes drug, may enhance the effectiveness of immunotherapy in treating lung cancer, particularly in obese patients. The study, led by Dr. Sai Yendamuri at Roswell Park Comprehensive Cancer Center, found that metformin's anticancer effects were significant only in overweight individuals, potentially due to its ability to mitigate obesity-related immune system damage. This discovery could lead to new treatment regimens and clinical trials focusing on metformin's role in cancer prevention and therapy for obese patients.